Trial Search Results

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time which patients will stay in remission from their disease.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ronald Levy

Collaborator: National Institutes of Health (NIH)


  • Biological: CpG-MCL vaccine
  • Biological: PF-3512676
  • Procedure: Vaccine-primed T-cells
  • Procedure: Autologous hematopoietic stem cell transplant (HSCT)
  • Drug: Rituximab
  • Drug: Standard induction chemotherapy
  • Drug: Cyclophosphamide
  • Drug: Filgrastim


Phase 2



   - Newly-diagnosed with mantle cell lymphoma (MCL) with accessible disease site for
   excisional biopsy, OR have sufficient peripheral blood tumor to leukapherese ≥ 1.5 x
   10e9 lymphoma cells in a single session

   - Medically appropriate by standard clinical criteria to receive rituximab and standard
   induction chemotherapy and high-dose chemotherapy with autologous hematopoietic cell
   transplant (AHCT)

   - HIV-negative

   - Eastern Cooperative Oncology Group (ECOG) Performance Status, OR Karnofsky performance
   scale 50 to 100%

   - Capable of providing informed consent


   - Currently receiving immunosuppressive medications

   - Severe psychological or medical illness

   - Pregnant or lactating

   - Unable to safely complete the study, at the discretion of the principal investigator

Ages Eligible for Study

21 Years - 70 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting